Orchid Bioscience, Ellipsis Enter IBD SNP-Discovery Pact | GenomeWeb

NEW YORK, Oct. 10 - Orchid BioSciences and Ellipsis Biotherapeutics have entered into a pharmacogenomics collaboration that will use Orchid’s SNPcode technology, the companies said on Wednesday.

Under the terms of the agreement Orchid will use its MegaSNPatron conduct high-throughput SNP-genotyping and construct high-density chromosome maps using clinical samples provided by Ellipsis. The partnership will initially study SNPs associated with inflammatory bowel disease, according to a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."